Human Immune Monitoring Shared Resource

摘要 概述：免疫疗法正在彻底改变癌症治疗。人类免疫监测共享 Resource（HIMSR）为基础和临床科学研究人员提供尖端的免疫监测检测， 对于癌症免疫疗法的持续发展至关重要。HIMSR的使命是促进临床和 通过解剖免疫机制进行转化研究，具有诊断和治疗应用，包括 发现新的生物标志物。HIMSR与研究界合作，开发、测试和实施新的 研究肿瘤免疫学的技术，并协助翻译研究人员选择适当的 确保临床样本与下游免疫相关检测兼容。服务：检测 提供包括免疫表型和功能表征的流式细胞仪和质谱仪， 荧光组织成像、多重细胞因子分析和细胞测定（体外杀伤、增殖、细胞内 细胞因子等）。这些检测对于了解最近开发的癌症免疫疗法的反应至关重要 例如转基因T细胞、疫苗和各种阻断和消耗抗体。HIMSR 与病理学共享资源（PSR）合作，提供临床样本处理，目前支持 22篇临床研究试剂/工具：支持研究者研究肿瘤中的免疫细胞浸润 微环境，HIMSR已获得高参数组织成像平台，包括Vectra 3.0，Vectra Polaris和多重离子束成像（MIBI）系统。SR已经开发了超过150种不同的7色和9色 目前，该公司正在为Vectra平台开发一个40参数的MIBI检测板。HIMSR 通过优化高参数流式细胞术和质谱细胞术面板，与流式细胞术SR（FCSR）合作， 由FCSR工作人员准备在FCSR仪器上运行的样品组。HIMSR还获得了一种多重蛋白质， 阵列仪器，以便于分析可溶性因子，如细胞因子和趋化因子。咨询和教育： HIMSR人员协助研究人员设计和优化定制的流式细胞仪、质谱仪和组织分析仪。 成像面板。他们帮助设计临床试验的研究终点，并与其他共享资源合作 以确保无缝访问所有必要的技术。HIMSR每月为研究者举办用户组会议 进行组织成像实验，并提供在线培训视频和研讨会， 图像分析软件。管理：HIMSR由人类免疫学和免疫疗法倡议管理 (HI3)由UCCC基础研究副主任监督。服务使用：自2018年7月起，HIMSR 与110名调查人员合作，其中49%是UCCC成员，代表了所有四个UCCC项目 共发表论文21篇。业务预算：通过此次更新，CCSG的资金提议为年度资金的7%。 运营预算，其余来自用户费用（56%）和机构支持（37%）。未来发展方向： 定制的面板和新技术将根据研究界的需要进行扩展，包括获得 Nanostring nCounter分子条形码技术和TCR/BCR测序。

ABSTRACT Overview: Immunotherapies are revolutionizing cancer treatments. The Human Immune Monitoring Shared Resource (HIMSR) provides basic and clinical science researchers with cutting-edge immune monitoring assays that are essential for the continued advancement of cancer immunotherapies. HIMSR's mission is to facilitate clinical and translational studies by dissecting immune-based mechanisms with diagnostic and therapeutic applications, including discovery of novel biomarkers. HIMSR partners with the research community to develop, test and implement new technologies for investigation of tumor immunology and assists translational researchers in selecting appropriate endpoints and ensures clinical samples are compatible with downstream immune-related assays. Services: Assays offered include immunophenotyping and functional characterization by flow and mass cytometry, multicolor fluorescence tissue imaging, multiplex cytokine analysis, and cellular assays (in vitro killing, proliferation, intracellular cytokines, etc). These assays are vital for understanding the response to recently developed cancer immunotherapies such as transfer of genetically modified T cells, vaccines, and various blocking and depleting antibodies. HIMSR collaborates with the Pathology Shared Resource (PSR) to provide clinical sample processing and currently supports 22 clinical studies. Reagents/Tools: To support investigators studying immune cell infiltrate in tumor microenvironments, HIMSR has acquired high parameter tissue imaging platforms, including the Vectra 3.0, Vectra Polaris, and Mutiplex Ion Beam Imaging (MIBI) systems. The SR has developed >150 different 7- and 9-color immunofluorescent panels for the Vectra platforms and is developing a 40 parameter panel for the MIBI. HIMSR collaborates with the Flow Cytometry SR (FCSR) by optimizing high parameter flow and mass cytometry panels, and preparing sample sets that are run on FCSR instruments by FCSR staff. HIMSR also acquired a multiplex protein array instrument to facilitate analysis of soluble factors like cytokines and chemokines. Consultation and Education: HIMSR personnel assist investigators in the design and optimization of customized flow, mass cytometry, and tissue imaging panels. They aid in the design of research endpoints for clinical trials, and work with other shared resources to ensure seamless access to all necessary technology. HIMSR hosts monthly user group meetings for investigators performing tissue imaging experiments and provides online training videos and workshops and remote access to image analysis software. Management: HIMSR is managed by the Human Immunology and Immunotherapy Initiative (HI3) with oversight by the UCCC Associate Director for Basic Research. Use of Services: Since July 2018, HIMSR has collaborated with 110 investigators, 49% of whom were UCCC members, representing all four UCCC programs and resulting in 21 publications. Operating Budget: With this renewal CCSG funding is proposed at 7% of the annual operating budget with the remaining from user fees (56%) and institutional support (37%). Future Directions: Customized panels and new technology will be expanded as needed by the research community, including access to Nanostring nCounter molecular barcoding technology and TCR/BCR sequencing.